MedPath

Reoperation Rate in Breast-Conserving Surgery Using Confocal Histolog® Scanner for Intraoperative Margin Assessment

Not Applicable
Completed
Conditions
Breast-Conserving Surgery
Breast Cancer - Ductal Carcinoma in Situ (DCIS)
Interventions
Device: Histolog Scanner
Registration Number
NCT05946759
Lead Sponsor
SamanTree Medical SA
Brief Summary

This PMPF study is proposed to evaluate in real life the reoperation rates (ROR) of breast cancer and/or DCIS surgery when including the use of the HLS in the context of breast lumpectomy margin assessment.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
54
Inclusion Criteria
  • Adult female Subject ≥18 years old.
  • Subject Scheduled for breast conserving surgery of invasive and/or in-situ ductal carcinoma.
  • Subject is able to read, understand and sign the informed consent.
Exclusion Criteria
  • Subject previously treated for ipsilateral breast cancer and/or ductal carcinoma in situ surgery.
  • Subject with previous radiotherapy of the ipsilateral breast.
  • Subject with multicentric/multilateral breast cancer.
  • Subject with planned mastectomy, tumor-adapted breast reduction.
  • Subject with pre-surgical/ preoperative neo-adjuvant treatment.
  • Subject is pregnant/ lactating.
  • Participation in any other clinical study that would affect data acquisition.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
ProspectiveHistolog Scanner50 prospective subjects
Primary Outcome Measures
NameTimeMethod
Reoperation Rate2-30 days post Breast Surgery

Differences in the rate of reoperation due to cancer positive margins

Secondary Outcome Measures
NameTimeMethod
Change in hospital cost with or without IVD device and accessories [Economic Impact]30 days post surgery date

To evaluate the economic impact for the hospital/payer of the reoperation rate

System Usability Scale (SUS) of the IVD device and accessories [Usability]Only during the time of the breast surgery

To survey usability of the HLS and accessories when used intraoperatively

Incidence of adverse device effects [Safety]Only during the time of the breast surgery

Incidence of adverse device effects during surgery

Margin status of intraoperative specimen vs. postoperative pathology assessment [Clinical Performance]0-30 days post Breast Surgery

To observe real life clinical performance of the HLS and accessories when used intraoperatively

Trial Locations

Locations (1)

St. Vincenz-Krankenhaus GmbH, Frauenklinik St. Louise

🇩🇪

Paderborn, Germany

© Copyright 2025. All Rights Reserved by MedPath